SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma

Clinical and Translational Oncology

Volumn 14, Issue 7, 2012, Pages 528-535

  Rivera, Fernando ^a   Grávalos, Cristina ^b   García Carbonero, Rocío ^c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Clinical guidelines; Diagnosis; Gastric adenocarcinoma; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CAUSE OF DEATH; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DIARRHEA; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HUMAN; MEDICAL SOCIETY; METASTASIS; NEUTROPENIA; PERIOPERATIVE PERIOD; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ALGORITHMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; SPAIN; STOMACH NEOPLASMS;

EID: 84864649856     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0836-9     Document Type: Article

References (33)

1. Parkin D, Pisani P, Ferley J et al (1999) Global cancer statistics. Ca Cancer J Clin 49:33-64
2. Crew KD, Neugut AI (2004) Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31:450-464
3. Hofmann M, Stoss OR, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
4. López-Ríos F, Concha A, Corominas JM et al (2011) Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico. Rev Esp Patol 44:32-48
5. Rivera F, Carrato A, Grávalos C et al (2009) Recommendations on current approach to gastric cancer. Clin Transl Oncol 11:518-525
6. Okines A, Verheij M, Allum W et al (2010) On behalf of the ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21[Suppl 5]:v50-v54
7. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303:1729-1737
8. Sakuramoto S, Sasako M, Yamaguchi T et al; ACTS-GC Group (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
9. Bang Y, Kim YW, Yang H et al (2011) Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the phase III CLASSIC trial. J Clin Oncol 29:[Suppl]:abstr LBA4002
10. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
11. Macdonald JS, Smalley S, Benedetti J et al (2004) Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). ASCO (abstr #6)
12. Fuchs CS, Tepper JE, Niedzwiecki D et al (2011) Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/ LV before and after CRT: intergroup trial CALGB 80101. J Clin Oncol 29[Suppl]:abstr 4003
13. Lee J, Lim do H, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273
14. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 355:11-20
15. Boige V, Pignon J, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25[18s]:Abst 4510
16. Schuhmacher C, Schlag P, Lordick F et al (2009) Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. J Clin Oncol 27[15s]:Abstr 4510
17. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856
18. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
19. Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:2004-2213
20. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
21. Cunningham D, Starling N, Rao S et al (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
22. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442
23. Kang AND, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non inferiority trial. Ann Oncol 20:666-673
24. Okines AF, Norman AR, McCloud P et al (2009) Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529-1534
25. Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547-1553
26. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457
27. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
28. Gravalos C, Marquez A, García-Carbonero R et al (2007) Correlation between Her2/neu overexpression/ amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium 130:Abstr 89
29. Gravalos C, Gomez-Martin C, Rivera F et al (2011) Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 13:179-184
30. Bang yJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
31. van Cutsem E, Shah M, Kang AND et al (2010) Randomized, double-blind, placebo-controlled, multicentre phase III study of capecitabine/cisplatin + bevacizumab (bev) or placebo (pl) as 1st-line therapy in patients (pts) with advanced gastric cancer (AGC) (AVAGAST update). ESMO Abst 713 P
32. Rao S, Starling N, Cunningham D et al (2010) Matuzumab plus epirubicin, cisplatin and capecitabin (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II trial. Ann Oncol 21:2213-2219
33. Thuss-Patience PC, Kretzschmar A, Deist T et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27(18s):Abstr 4540